EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

被引：0
|
作者：
Wang, L. [1 ]
Su, S. [2 ,3 ]
Lv, X. [2 ,3 ]
Liu, Y. [2 ,3 ]
Chen, F. [2 ,3 ]
Shao, J. [2 ,3 ]
Liu, B. [2 ,3 ]
机构：
[1] Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China
[2] Nanjing Univ, Sch Med, Nanjing Drum Tower Hosp, Ctr Comprehens Canc, Nanjing, Peoples R China
[3] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Clin Canc Inst, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Neoantigen vaccine; EGFR mutation; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4.11D.05
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 50 条
  • [31] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [32] Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Kim, Sang-We
    Lee, Ki Hyeong
    Kim, Dong-Wan
    Lee, Yun-Gyoo
    Cho, Eun Kyung
    Lee, Gyeong-won
    Lee, Jong-Seok
    Kim, Joo-Hang
    Kim, Jin-Soo
    Min, Young Joo
    Lee, Sung Sook
    Shin, Sang Won
    Kim, HyeRyun
    Hong, Min Hee
    Ahn, Jin Seok
    Lee, Seoung Oh
    Kim, Sohee
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC
    Charonpongsuntorn, Chanchai
    Incharoen, Pimpin
    Trachu, Narumol
    Muntham, Dittapol
    Kampreasart, Kaettipong
    Saowapa, Sakdiat
    Sirichainan, Ekaphop
    Reungwetwattana, Thanyanan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1196 - S1196
  • [34] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Zhuchen Yu
    Fei Xu
    Juntao Zou
    European Journal of Clinical Pharmacology, 2024, 80 : 505 - 517
  • [35] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Yu, Zhuchen
    Xu, Fei
    Zou, Juntao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) : 505 - 517
  • [36] Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study
    Peng, P.
    Chen, Y.
    Han, G.
    Meng, R.
    Zhang, S.
    Liao, Z.
    Zhang, Y.
    Gong, J.
    Xiao, C.
    Liu, X.
    Zhang, P.
    Zhang, L.
    Xia, S.
    Chu, Q.
    Chen, Y.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S250 - S251
  • [37] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [38] EGFR-TKI resistance in NSCLC patients: mechanisms and strategies
    Lin, Yuxin
    Wang, Xian
    Jin, Hongchuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2014, 4 (05): : 411 - 435
  • [39] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, (04) : 270 - 276
  • [40] EGFR-TKI Treatment and Surgical Resection for Oligometastatic NSCLC?
    Klomp, Houke M.
    Kappers, Ingrid
    ONKOLOGIE, 2009, 32 (11): : 627 - 628
12345